GLP1 Clinical Trial Eye Safety: The Data Is Piling Up 4x Increased Risk of NAION with Semaglutide In a landmark 2024 study published in JAMA Ophthalmology, researchers followed diabetic and obese patients exposed to semaglutide
Remember, sustainable weight loss and diabetes management require a comprehensive approach including diet, exercise, and medical supervision
Lukinaviius, G
If your replacement dose stays fixed while your weight drops, you may develop signs of overreplacement: rapid heart rate, anxiety, heat intolerance, or tremor
Wegovy tablets are FDA-approved for adults who meet at least 1 of these: BMI of 30 or higher (classified as obesity) BMI of 27 or higher plus at least 1 weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol Within that group, the pill may be especially worth discussing with your doctor if: You have needle anxiety or a strong preference to avoid injections
But semaglutide the active pharmaceutical ingredient in Wegovy is widely available, says Scott Brunner, CEO of the Alliance for Pharmacy Compounding